Tarsons Products Limited has issued a postal ballot notice seeking shareholder approval for the appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director. The notice, dated March 06, 2026, follows the company's earlier intimation to stock exchanges regarding the Board of Directors' decision to appoint Mr. Kriplani to the position.

Appointment Details and Timeline

The proposed appointment seeks to designate Mr. Vinesh Mohan Kriplani (DIN: 08212644) as Non-Executive Independent Director for a term of five consecutive years. The appointment period extends from February 06, 2026 to February 05, 2031, and the director will not be liable to retire by rotation.

E-Voting Process and Key Dates

The company has engaged National Securities Depository Limited (NSDL) to provide remote e-voting facility to shareholders. The voting process will be conducted exclusively through electronic mode, with no physical postal ballot forms being distributed to members.

Director Profile and Qualifications

Mr. Vinesh Mohan Kriplani brings extensive experience in corporate finance and taxation to the board. Born on November 21, 1972, he is a Chartered Accountant with over 29 years of experience in Indian corporate and international taxation, specializing in mergers and acquisitions, corporate restructuring, and cross-border transactions.

Currently associated with the Poonawalla Group through Serum Institute of India, Mr. Kriplani leads M&A and international tax matters, advising senior leadership on strategic growth initiatives. His expertise spans transfer pricing, tax dispute resolution, valuations, and foreign exchange regulations.

Professional Background

Mr. Kriplani has previously held senior leadership roles with Ernst & Young, KPMG, and PricewaterhouseCoopers, including serving as Senior Partner at EY India, where he built and led a market-leading tax practice. He has worked across India and Hong Kong, advising multinational clients on complex transactions. He is also a co-founder of Transaction Square LLP and has served at the Board level of a regulated NBFC.

Current Directorships and Committee Memberships

Mr. Kriplani currently serves as a director of Magma General Insurance Limited, where he holds memberships in key committees:

• Audit Committee – Member
• Investment Committee – Member

Regulatory Compliance and Documentation

The company has received all statutory disclosures and declarations from Mr. Kriplani, including consent to act as director, confirmation of independence criteria compliance, and various regulatory clearances. The Nomination and Remuneration Committee had previously finalized the desired attributes for Independent Director selection and recommended Mr. Kriplani's candidature based on his experience, expertise, and independence.

The postal ballot notice is available on the company's website at www.tarsons.com and on NSDL's website at www.evoting.nsdl.com . Shareholders whose email addresses are registered with the company, depositories, or depository participants as on the cut-off date will receive the notice electronically.

Source: None/Company/INE144Z01023/15cd636d-1314-4d48-9596-031e551d2016.pdf

Tarsons Products has released the complete transcript of its Q3FY26 earnings conference call held on February 06, 2026, providing detailed insights into the company's financial performance and strategic outlook. The transcript, uploaded to the company's website and shared with stock exchanges under Regulation 30 of SEBI regulations, offers comprehensive management commentary on quarterly results and operational developments.

Conference Call Documentation and Compliance

The company formally notified BSE and NSE on February 11, 2026, about the availability of the earnings conference call transcript. The document was digitally signed by Santosh Kumar Agarwal, CFO, Company Secretary & Compliance Officer, ensuring regulatory compliance and transparency for stakeholders.

Q3FY26 Financial Performance Highlights

During the conference call, management discussed the company's mixed financial performance for Q3FY26. Consolidated revenue grew 12.8% year-on-year to ₹1,078.93 million, while net profit declined to ₹50.36 million from ₹52.59 million in Q3FY25. The company emphasized evaluating performance on cash PAT basis due to accelerated depreciation from new facility investments.

Strategic Capacity Expansion and New Product Lines

Management highlighted the partial commissioning of the Panchla facility, with bioprocess containers already in production and generating sales in domestic and international markets. The facility has potential revenue capacity exceeding ₹150.00 million at full utilization. Cell culture products are expected to commence production in Q4FY26, requiring initial sampling and customer validation processes.

Aryan Sehgal, Promoter & Whole Time Director, emphasized the company's positioning to capitalize on government initiatives supporting the biopharmaceutical sector, including the ₹100.00 billion allocation over five years for India's biologics ecosystem development.

Market Dynamics and Competitive Landscape

The management addressed competitive pressures in domestic markets, attributing pricing challenges to excess capacity created during the COVID period. Despite competitive headwinds, the company reported operating at near full capacity in existing plants and expects stronger revenue growth in FY27 as new capacities ramp up.

International Business and Trade Agreements

Management expressed optimism about international market prospects following potential India-EU and India-US trade agreements. The India-US FTA could provide significant benefits by reducing tariffs from 50% to 18%, while the India-EU FTA would eliminate the current 6% duty. The company's German subsidiary Nerbe showed 22% revenue growth in Q3FY26, primarily due to rupee depreciation against the Euro.

Working Capital and Inventory Management

CFO Santosh Agarwal detailed the company's working capital cycle of 125 days, with inventory comprising raw materials worth ₹41.00 million, finished goods worth ₹39.00 million, and other components. The management expects inventory optimization as revenue scales up with new product launches and capacity utilization improvements.